Safety, Tolerability, PK and PD of Single Rising Oral Doses of BI 1569912 in Healthy Male Subjects

Phase 1, randomised, single-blind trial of BI 1569912 (14 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number of Subjects With Drug-related Adverse Events up to 14.5 days, Area Under the Concentration-time Curve of BI 1569912 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point up to 72 hours and 1 more. Started Jul 2020; status: terminated.